1. ¹2nd Department of Pathology, Semmelweis University, Budapest, Hungary
2. ²1st Department of Surgery, Semmelweis University, Budapest, Hungary
3. ³First Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
4. ⁴Department of Molecular Pathology, Joint Research Organization of the Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary

Correspondence: Dr Z Schaff, MD, PhD, DSc, 2nd Department of Pathology, Semmelweis University, Ülli út 93, H-1091 Budapest, Hungary. E-mail: schaff@korb2.sote.hu

^*These authors contributed equally to this study.

Received 26 August 2005; Revised 8 December 2005; Accepted 8 December 2005; Published online 20 January 2006.

Abstract

The recently identified claudins are dominant components of tight junctions, responsible for cell adhesion, polarity and paracellular permeability. Certain claudins have been shown to have relevance in tumor development, with some of them, especially claudin-4, even suggested as future therapeutic target. The aim of the present study was to analyze the expression of claudin-4 in the biliary tree, biliary tract cancers and hepatocellular carcinomas. A total of 107 cases were studied: 53 biliary tract cancers, 50 hepatocellular carcinomas, 10 normal liver and 10 normal extrahepatic biliary duct samples. Immunohistochemical analysis was performed on conventional specimens and on tissue microarrays as well. Claudin-4 was further investigated by Western blot analysis and real-time RT-PCR. Intense membranous immunolabeling was found for claudin-4 in all biliary tract cancers unrelated to the primary site of origin, namely intrahepatic, extrahepatic or gallbladder cancers. Normal biliary epithelium showed weak positivity for claudin-4. In contrast, normal hepatocytes and tumor cells of hepatocellular carcinomas did not express claudin-4. The results of Western immunoblot analysis and real-time RT-PCR were in correlation with the immunohistochemical findings. Cytokeratins, as CK7 (92%) and CK19 (83%) were mostly positive in biliary tract cancers, however, one-third of hepatocellular carcinomas also expressed CK7 (34%). HSA antibody (HepPar1) reacted with the majority of hepatocellular carcinomas (86%), while being positive in a low percentage of the biliary tract cancers (8%). In conclusion, this is the first report of a significantly increased claudin-4 expression in biliary tract cancers, which represents a novel feature of tumors of biliary tract origin. Claudin-4 expression seems to be a useful marker in differentiating biliary tract cancers from hepatocellular carcinomas and could well become a potential diagnostic tool.